Asset profile
COM902
Monoclonal antibody
Evidence outlook · lead readout
NCT04354246 · Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04354246: There was no randomization to a placebo or comparator treatment and no blinding: every one of the six groups received an active dose or combination of COM902. The main goals were safety, tolerated dose, and drug levels, with tumor response collected only as an exploratory measure, and results have not been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.